Objective   To study the specific anti-tumor immunity of dendritic cell (DC) modified by HSP70-tumor peptide complexes and sCD40L in vitro and in vivo.     Methods   The murine marrow cells were cultured for 7 d

and then randomized to 4 groups: control

only HSP70-H22 peptide complexes

sCD40L

and HSP70-H22 peptide complexes combined with sCD40L. After intervention for 24 h

IL-12 and IL-10 in the supernatant were detected by ELISA assay

CD40 and CD80 of DC by FACS

and the proliferation of spleen lymphocytes by MRL. The ability of spleen lymphocytes activated by DC to H22 cells in vitro was investigated by MTT. The models of murine hepatoma were established

and then randomized to 5 groups (Ⅰ

Ⅱ

Ⅲ

Ⅳ and Ⅴ)

followed by interference with normal saline and DC respectively. At 21 d

mice were sacrificed and the weight of tumor was measured. The levels of IL-10 and IFN-γ in blood serum were detected by ELISA assay.     Results   Compared with that in the groups of control

only sCD40L

and HSP70-H22 peptide complexes

the level of IL-10 in the group stimulated by HSP70-H22 peptide complexes combined with sCD40L decreased significantly

but other indexes in this group increased significantly (P0.05). Compared with that in groupsⅠ

Ⅱ

Ⅲ and Ⅳ

the level of IL-10 and the tumor weight in group Ⅴ decreased significantly

but the level of IFN-γ increased significantly (P0.05).     Conclusion   Sufficient activation of DC modified by HSP70-tumor peptide complexes and sCD40L can induce powerful specific antitumor immunity

strong killing effect against H22 cells

and efficient inhibition of tumor growth.